Biocon Plots Biosimilars Listing By 2023
Indian Firm Eyeing $1bn In Sales From Biosimilars In Two Years
Biocon has high ambitions for its biosimilars arm, Biocon Biologics, with planned revenues of $1bn by the end its financial year ending in March 2022. The Indian firm, which has collaborated with Mylan for multiple biosimilar launches in developed markets, is aiming to list the business within three years.
